Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Boston Scientific Q3
Boston Scientific Q3 Earnings Preview
In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration
Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory approvals on the stock. Click for more on BSX.
Boston Scientific’s stock climbs on Q3 sales and earnings beat
Boston Scientific’s BSX net income was $469 million, or 32 cents a share, down from $505 million, or 34 cents a share, in the same period last year. On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share.
MassDevice
1d
Boston Scientific still expects Axonics deal to close this year, posts Street-beating Q3
Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...
1d
on MSN
Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges
Key Takeaways Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates.The medical device maker's ...
1d
Boston Scientific Q3 Earnings: Revenue And EPS Beat, Lifts Annual Forecast On Strong Demand For Heart Devices
On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter revenues of $4.21 billion, beating the ...
1d
Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
11h
Boston Scientific price target raised to $98 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Boston Scientific (BSX) to $98 from $95 and keeps an Outperform rating on the shares. The ...
19h
Five things: Tax compromise, community colleges, Boston Scientific, GE Vernova and the Sacred Cod
Good morning, Boston. Here are the five things you need to know in local business news to start your busy Thursday.
1d
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Boston Scientific's AVANT GUARD trial evaluates the FARAPULSE PFA System for treating persistent atrial fibrillation, pausing ...
15h
Boston Scientific’s Robust Performance and Growth Prospects Drive Buy Rating
William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Q3
New York Stock Exchange
FARAPULSE
Trade
Food and Drug Administration
Feedback